American Hospital of Paris and OncoDNA announced a new joint initiative that is intended to advance the use of precision medicine in routine clinical practice for patients with metastatic breast cancer.
This one-year project called “Arche Profiler” aims at unlocking the potential of precision oncology in the clinical management of metastatic breast cancer patients; and creating a learning environment about the impact of comprehensive molecular profiling on therapeutical decisions. Through this partnership, advanced breast cancer patients will benefit from OncoDNA testing solutions (OncoDEEP, OncoSTRAT&GO, BRCAness and OncoSELECT) and physicians will gain actionable clinical insights to better drive personalized treatment plans, inclusive of chemotherapies, targeted therapies, immunotherapies and clinical trials.
“The then imprecise ‘one-size-fits-all’ approach in precision oncology, where patients with the same diagnosis were treated with the same drug, and is now moving to an approach where they are stratified by performing advanced molecular diagnostic tests on the solid biopsy in order to best guide treatment decision” said Myriam Guiral, OncoDNA’s CCO. “We are excited to partner with American Hospital of Paris on this Arche Profiler initiative and to help deliver high-quality and valuable personalized medicine insights at the point of care for the benefit of patients”.
“This partnership is a unique opportunity that will allow our patients to benefit from the latest advances in molecular profiling and personalized approaches that will be made available in the coming years.”, said Mahasti Saghatchian, head of the breast onco-unit at American Hospital of Paris. “The end goal of our project is to help expand our ability to deliver comprehensive and cutting-edge precision oncology services for every breast cancer patient. Understanding the molecular landscape of a patient’s cancer in order to define the appropriate treatment course for patients with advanced cancer over multiple lines of therapy is key to move patient care forward, and we are happy OncoDNA is joining us on that path.”
About American Hospital of Paris
Founded in 1906, the American Hospital of Paris is a not-for-profit multidisciplinary healthcare institution of recognized public benefit, whose mission is to deliver premium personalized medical care to French, American and international communities living in France and abroad. True to its mission and history, the American Hospital of Paris places quality and safety at the heart of its practices, complying with the highest medical standards and being accredited by both the American Joint Commission and the French Haute Autorité de Santé. Its medical staff comprises approximately 350 bilingual private practice physicians covering all major medical and surgical disciplines. Beyond its indisputably excellent medical care, the American Hospital of Paris takes pride in offering high-quality amenities to patients and their loved ones. Many services are available so they may benefit from the highest standards of comfort and peace of mind. According to the Haute Autorité de Santé, the American Hospital is France’s top-ranking healthcare institution in terms of patient satisfaction.
OncoDNA is a private, oncology-focused healthcare technology company that combines advanced, comprehensive testing of all clinically relevant cancer biomarkers (DNA, RNA and protein profiles) from both solid and liquid biopsies with a proprietary cancer treatment knowledge database called OncoKDO™ which continuously ‘learns’ from cutting-edge, validated, scientific and medical advances. This one-stop-shop analysis and interpretation service gives oncologists actionable results to enable the selection of treatments tailored to the individual patient’s cancer profile. For laboratories worldwide with NGS facilities who would like to reach the same level of expertise, we provide them with state-of-the-art interpretation software to improve their oncology-oriented analyses routine work. The software OncoKDM is a web-based tool that processes oncology raw NGS data to turn data into clinical insight such as treatment options or clinical trials. OncoDNA also works in collaboration with the biopharma industry to develop and deliver the treatments of tomorrow by assisting with design, enrolment and assessment of clinical trials as well as increasing access to approved precision medicines. The company is based in Gosselies, Belgium, employs approx. 50 employees in four countries, works with an international network of 35 distributors covering approx. 50 countries and is collaborating with a sub-contracted laboratory of 300 collaborators.